|Mr. Kyle Detwiler||CEO & Chairman||N/A||N/A||1983|
|Mr. AndrÃ©s Fajardo||Pres & Director||N/A||N/A||1978|
|Mr. Henry R. Hague III||Chief Financial Officer||N/A||N/A||1973|
|Mr. David M. Kastin Esq.||Gen. Counsel & Corp. Sec.||N/A||N/A||1968|
|Diana SigÃ¼enza||Strategic Communications Director||N/A||N/A||N/A|
|Mr. Amit Pandey||Exec. VP of Fin.||N/A||N/A||1982|
|Mr. Julian Wilches||Chief Regulatory Officer||N/A||N/A||1979|
|Mr. Andrew Miller||Head of Commercial Global (Ex-LatAm)||N/A||N/A||N/A|
|Mr. Gustavo Escobar||Head of Commercial, Latin America||N/A||N/A||N/A|
Clever Leaves Holdings Inc. cultivates, produces, and sells pharmaceutical-grade cannabinoids in the United States, Colombia, Portugal, Germany, and Canada. It also engages in the formulating, manufacturing, marketing, distributing, and selling of homeopathic and other natural remedies, wellness products, and nutraceuticals. The company was formerly known as Northern Swan Holdings, Inc. and changed its name to Clever Leaves Holdings Inc. in March 2020. Clever Leaves Holdings Inc. was incorporated in 2017 and is based in New York, New York.
Clever Leaves Holdings Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.